Download PDF

1. Company Snapshot

1.a. Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.It operates in two segments, Nucleic Acid Production and Biologics Safety Testing.


The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology.The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.


This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services.The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies.Maravai LifeSciences Holdings, Inc.


was incorporated in 2020 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on MRVI

Maravai LifeSciences Holdings, Inc.'s recent performance was driven by the appointment of Rajesh Asarpota as Chief Financial Officer, effective June 30, 2025. This strategic move is expected to bring nearly three decades of executive leadership experience to the company, including over 10 years as CFO of both public and private life sciences and medical device companies. Additionally, the company's recent earnings release highlighted its growth and performance, with Mr. Asarpota's appointment being a key factor in driving the company's future growth.

1.c. Company Highlights

2. Maravai LifeSciences Faces Challenges Amidst Revenue Decline

Maravai LifeSciences reported a total revenue of $41.6 million for Q3 2025, a significant decline from $69 million in Q3 2024. The company's Nucleic Acid Products segment contributed $25.4 million, declining 53% year-over-year, while Biologic Safety Testing generated $16.3 million, growing at 7%. The actual EPS came out at '-0.08', relative to estimates at '-0.06', indicating a wider loss. The company's adjusted EBITDA loss is expected to be roughly $35 million for 2025, with a loss of $3.5 million in Q4.

Publication Date: Nov -12

📋 Highlights
  • Q3 Revenue Composition:: Total revenue was $41.6M, with Biologic Safety Testing (BST) at $16.3M (7% growth) and Nucleic Acid Products (NAP) at $25.4M (53% decline YoY).
  • Cost Reduction Progress:: Annualized expense reduction of >$50M achieved, with >$7M sequential EBITDA improvement expected in Q4 2025.
  • 2025 Financial Outlook:: Anticipated full-year revenue of $185M, including Q4 growth of 18% over Q3 2025, and adjusted EBITDA loss of $35M (vs. $3.5M loss in Q4 2025).
  • CleanCap Pipeline:: $10–$20M revenue contribution expected in 2026, with 50% of savings from labor cost reductions and 40% from facilities/COGS.

Segment Performance

The Biologic Safety Testing segment continues to perform well, with strength in the U.S. and European markets, driven by broad adoption across novel monoclonal antibodies, biosimilars, and gene therapy products. In contrast, the Nucleic Acid Products segment faced challenges, with a decline in revenue due to order timing in the GMP and CDMO businesses. However, the company expects strong top-line growth for NAP in Q4, with the majority of orders already in hand.

Outlook and Guidance

The company anticipates closing 2025 with revenue of approximately $185 million, implying Q4 growth of 18% over the third quarter. Excluding GMP COVID CleanCap, Q4 base business growth is expected to be 16% year-over-year. Analysts estimate next year's revenue growth at 9.7%. The company's restructuring efforts are expected to lower annualized expenses by greater than $50 million.

Valuation Metrics

With a P/S Ratio of 8.88 and an EV/EBITDA of -9.21, the company's valuation metrics indicate a challenging financial situation. The ROE is -42.64%, and the ROIC is -4.71%, suggesting that the company is struggling to generate returns on its investments. The Net Debt / EBITDA ratio is 1.28, indicating a manageable debt burden.

3. NewsRoom

Card image cap

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates

Feb -26

Source: zacks.com

Card image cap

Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Wednesday

Feb -23

Source: defenseworld.net

Card image cap

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

Feb -09

Source: businesswire.com

Card image cap

Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Feb -05

Source: defenseworld.net

Card image cap

General American Investors Co. Inc. Takes Position in Maravai LifeSciences Holdings, Inc. $MRVI

Jan -27

Source: defenseworld.net

Card image cap

Maravai LifeSciences (NASDAQ:MRVI) & Capricor Therapeutics (NASDAQ:CAPR) Critical Review

Jan -12

Source: defenseworld.net

Card image cap

Investors Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Nov -27

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.22%)

6. Segments

Nucleic Acid Production

Expected Growth: 10.2%

Growing demand for nucleic acid-based therapies, increasing adoption of genetic testing, and advancements in gene editing technologies drive the growth of the nucleic acid production market.

Biologics Safety Testing

Expected Growth: 10.3%

Increasing demand for biologics, growing need for safety testing, and advancements in biotechnology drive the growth of biologics safety testing market.

Eliminations

Expected Growth: 12.3%

The elimination of intercompany transactions and balances from Maravai LifeSciences Holdings, Inc. is expected to drive growth, driven by increasing demand for consolidated financial reporting, improved transparency, and enhanced investor confidence.

7. Detailed Products

Nucleic Acid Production

Maravai LifeSciences provides nucleic acid production services, including DNA and RNA synthesis, purification, and modification, for research, diagnostic, and therapeutic applications.

Gene Expression Analysis

Maravai offers gene expression analysis services, including RNA extraction, sequencing, and data analysis, to help researchers understand gene expression and regulation.

Protein Production

Maravai provides protein production services, including protein expression, purification, and modification, for research, diagnostic, and therapeutic applications.

Antibody Development

Maravai offers antibody development services, including antibody discovery, optimization, and production, for research, diagnostic, and therapeutic applications.

Molecular Diagnostics

Maravai provides molecular diagnostic products and services, including PCR, qPCR, and NGS, for infectious disease detection, genetic testing, and cancer diagnostics.

8. Maravai LifeSciences Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Maravai LifeSciences Holdings, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the biotechnology industry.

Bargaining Power Of Customers

Maravai LifeSciences Holdings, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Maravai LifeSciences Holdings, Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size, suppliers still have some leverage due to the specialized nature of the products.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements and regulatory hurdles. This makes it difficult for new entrants to compete with established companies like Maravai LifeSciences Holdings, Inc.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established companies competing for market share. Maravai LifeSciences Holdings, Inc. faces intense competition from companies with similar product offerings and research capabilities.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 56.05%
Debt Cost 3.95%
Equity Weight 43.95%
Equity Cost 4.09%
WACC 4.01%
Leverage 127.55%

11. Quality Control: Maravai LifeSciences Holdings, Inc. passed 1 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
OncoCyte

A-Score: 4.7/10

Value: 7.1

Growth: 5.9

Quality: 3.1

Yield: 0.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Kezar Life Sciences

A-Score: 3.7/10

Value: 8.0

Growth: 5.6

Quality: 4.2

Yield: 0.0

Momentum: 3.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Biomea Fusion

A-Score: 3.3/10

Value: 6.9

Growth: 3.4

Quality: 4.1

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Allogene Therapeutics

A-Score: 3.0/10

Value: 7.6

Growth: 4.3

Quality: 4.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Pliant Therapeutics

A-Score: 2.6/10

Value: 8.0

Growth: 3.1

Quality: 3.5

Yield: 0.0

Momentum: 0.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Maravai LifeSciences

A-Score: 2.5/10

Value: 7.1

Growth: 2.1

Quality: 3.9

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.55$

Current Price

3.55$

Potential

-0.00%

Expected Cash-Flows